Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BioGaia, Audiocast, Q3'25

By Inderes10/22/2025, 7:30 AM
BioGaia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Theresa Agnew
00:00 - 09:25

Hi, this is Theresa Agnew, CEO of BioGaia. And Alex and I are here to present our Q3 results. So sales were 327 million SEK, which is an increase of 7% due to higher sales in the Americas as well as the Asia Pacific. Growth overall was 14% when excluding currency effects. Year to date, our growth is 8% excluding currency effects and 4% including currency. Our sales in the Asia Pacific for the quarter increased by 17%, in the Americas increased by 10%, and in EMEA decreased by 4%, primarily due to sales in Eastern Europe. We saw strong growth following increased media investments in the US and among other priorities. We prioritized direct markets such as Canada, the UK, and Australia. With our increased media, we've been attracting new consumers to the brand and enhancing our brand awareness for the quarter. Our EBIT is 86 million SEK and our EBIT margin is 26%. And as you can see, this compares to a 14% EBIT margin last year. This was lower due to the impairment loss of 51 million. Our year-to-date EBIT margin is now 27%. Just to remind you of our BioGaia company strategy, we have three strategic pillars. The first is Grow the Core, in which we focus on gut health, colic, oral health, as well as immune health. Our second focus is expansion through direct markets. And our third is breakthrough innovation. This is where market creation opportunities arise for using probiotics in new areas. The foundations of our company are, of course, our people and culture. Investing for profitable growth, digital as an enabler of our business as well as our go-to-market driven by science, which has been a foundation for over 30 years for the company, and sustainable solutions with a strong focus on sustainability, we are delivering on our strategy in terms of our Grow the Core. We're driving growth in our pediatric and adult health segments. We're investing in marketing and sales activities to drive strong growth in our direct markets. As I mentioned, in the US, we're successfully launching new products in our core health areas. Last year we launched BioGaia Gastrus Pure Action, and this quarter we're rolling it out to more markets. This quarter, we also launched Prodentis Fresh Breath, which is a new product that combines our probiotics with zinc. It works on gums and teeth, as well as providing fresh breath. We're rolling out many of our other products in partner markets and direct markets as well. In terms of our second strategy, expansion through direct markets, we launched France as a direct market in Q2. And that market is starting to do well. In Q3, we're preparing to launch Germany and Austria in early 2026. And actually, in Q3, France had its strongest month with record sales in September. So, we have high ambitions in France to continue our growth into next year. Australia, which we launched in 2024. Now, with all of our marketing and selling efforts, BioGaia Protectis Easydropper is number one in the market. We also have record sales in the US market due to the investments that we've been putting into that market. Our direct markets are growing ahead of our partner markets in terms of our third strategic area, breakthrough innovation. As you may have seen in a press release, we've established a new subsidiary called BioGaia New Sciences AB that will focus on skin health, which is a new breakthrough innovation area for us. We are rolling out our BioGaia Probiotic Ointment to more markets. So now you will see we have new launches of our probiotic ointment. So speaking of launches, this shows you all the product launches we have had as we expand our new products into more markets for the quarter. We have rolled out our probiotic ointment in Sweden, Finland, and the UK. We launched Prodentis Fresh Breath lozenges. As I mentioned in the US, in Argentina we rolled out a number of our products, Slovakia and in the US. We launched our BioGaia Gastrus Pure Action capsules, which we first introduced in Finland last year. And then, we also rolled out Gastrus Pure Action capsules in Australia and New Zealand. All of these launches are doing very well, especially Gastrus Pure Action. It is driving increased sales in our adult gut health area. As well. It's continuing to do extremely well in Finland after a year of launch without cannibalizing our chewable Gastro product. Some of the key events that happened during the quarter, as I said, we launched our BioGaia New Sciences AB subsidiary at an extraordinary general meeting in August. We resolved to elect Mauricio Graber as our new chairman of the board. Also, Mauricio entered into an agreement to purchase some class B shares from the anchor shareholder Anatom Holding. BioGaia also announced a distribution agreement in Germany and Austria, which we will be starting in early 2026. We also announced the launch of a new product, Prodentis Fresh Breath. And as I said, it launched first in the US in the quarter. And more recently, we announced the publication of a study on our new patented strain, L. reuteri BG-R46. This has actually been published in a journal called Beneficial Microbes. We also introduced a press release on this, highlighting how, as expected, this new patented strain is safe and well characterized. In terms of sales per segment. In our Pediatrics area, sales grew by 7% this quarter. And if you exclude currency effects, it's 14%. This is mainly due to increased sales protecting against the US drop in Asia Pacific. Latin America specifically. Some markets that did very well were Indonesia, Vietnam, and Mexico. In terms of adult health, our sales increased by 6% in the quarter, rising to 13% when excluding currency effects. We saw particularly strong growth for BioGaia in the US. And as you can see, our Pediatric segment remains at about 75% of our sales. In terms of the regions, as I said earlier, EMEA sales decreased by 4%. This was mainly due to Eastern Europe and Italy. But one comment on Italy: Italy is growing well for us this year, so the decline that we saw was mainly due to order variability because we saw higher orders in Q2 in France. As I said, we achieved record sales in September. We are driving increased distribution. We're driving recommendations through pharmacies. So we anticipate that this growth will continue. And in Turkey, we have signed a long-term distribution agreement with one of our partners, Abbott. Abbott is actually a long-standing BioGaia partner. We partner with them in the Middle East, Latin America, and some other Asia Pacific markets. So we have now signed an agreement with Abbott Turkey for the market of Turkey. In Asia Pacific, our sales increased by 17%. This was mainly seen in Vietnam, as well as Indonesia and specifically in Australia. In one of our direct markets, we are expanding distribution, increasing our marketing activities, and growing our market share in the Americas. Our sales increased by 10%. This was mainly due to the growth in the US and Mexico, particularly in the US. We're achieving record-breaking sales. In the quarter. We successfully launched two new products, as I mentioned, which are BioGaia Gastrus Pure Action capsules and BioGaia Prodentis Fresh Breath. Both products are off to a fast start in the US. So I will now turn it over to Alex to go through our financials in more detail.

Alexander Kotsinas
09:25 - 13:41

Thank you, Theresa. So if we just summarize the key financials, we see that our sales grew by 7% from 304 million to 327 million. Our gross profit grew by 9%. And our EBIT grew by 8% from 41 million to 86 million, with a margin of 26% in the quarter versus 14% in the same quarter last year. If we look at the sales, as we heard previously, we had a sales growth of 7%; however, excluding currency effects, we had an organic growth of 14%. The gross margin improved from 73% last year to 74% this year, mainly due to an improved margin in Pediatrics, which is the largest segment, but also an improvement in the Adult Health segment. The main explanation for the improved margin is the difference in geographical sales compared to a year ago. More favorable geographic shift. For example, in direct markets where we have a higher gross margin, partly due to some price improvements and price increases that we made during the last year, which are obviously impacting the margin positively year to date. Then we have a gross margin, which is flat compared to a year ago. Uh, down 1% in Pediatrics, however, up 6% in Adult Health. Move on to our expenses. Our total expenses were 157 million in the quarter, which is 13% lower compared to one year ago. If we look at the different lines, sales and marketing costs were 116 million this year compared to 96 million last year, marking an increase of 21%. This is an effect of increased spending on marketing activities, mainly in our subsidiaries. And then mainly, of course, in North America and the US, where we have the largest operations. And that is why the sales and marketing costs have increased due to those increased investments. In terms of R&D, R&D costs decreased to 26 million due to the impairment loss, which Teresa mentioned previously, and which we took in the same quarter last year. Administration costs amounted to 11 million, reflecting an increase of 18%. There are some startup-related costs included in this line due to going direct. Other than that, it's basically the same costs. And then we have other operating expenses, which are basically exchange losses on receivables at a cost of 4 million in the quarter. And it's also worth noting that there's a substantial cost year to date amounting to 33 million. If we move on to the next section, the profit and loss, just to summarize, our sales grew 7% while our costs grew 13%. And therefore, our EBIT, the adjusted EBIT, declined by 8%. And the adjustment, again, was due to this impairment loss from one year ago. If we move on to the cash flow, the cash flow from operating activities increased by 10 million to 110, mainly due to a positive change in working capital. And the positive change in working capital is related to lower receivables. We had quite high sales in the second quarter this year, and a lot of those payments came in the third quarter, so the receivables decreased by 49 million. We had higher payables of 2 million, which was offset by higher inventory of 10 million. All of these variations are basically normal variations that we have. There's nothing one-offs or anything like that. And that leads to a cash flow for the period of 107 million versus 111 million last year. So basically a flat cash flow, and a cash at the end of the period of 728 million versus 1.11 billion in the same quarter last year. So with that, I hand over to Theresa for some concluding remarks.

Theresa Agnew
13:42 - 16:09

So in summary, as we said in the third quarter, our overall organic growth was 14% and an overall increase of 7%. And if you look year to date, we also grew 8% organically and up 4% with the currency effects. In the pediatric segment, we grew 7% in the quarter, and 14% excluding the foreign currency effects. 16%, as well as 20%, excluding the currency exchange effects. We're seeing particularly strong growth of our BioGaia product line, which falls into our adult gut health segment, as well as the BioGaia Prodentis, which falls into our oral health segment in the US. In the Americas and Asia Pacific, both regions delivered double-digit growth. Sales in EMEA declined slightly compared to the same quarter last year. And as we said, that was primarily driven by weaker performance in Eastern Europe. We are investing in marketing and selling activities this year to drive strong growth in our direct markets. We have seen a nice result from that, with strong double-digit growth in the quarter and year-to-date in the US. Some of this is obviously offset by currency effects, as well as lower sales in EMEA due to certain partners. And when we establish direct markets, we typically see lower sales upfront because our partners are usually selling through their prior inventory. So as we are establishing these direct markets in France and Germany, we'll see some lower sales. And then that will pick up once the prior inventory is sold through. So the strong double-digit growth in the markets where we're investing is offset by these factors. Our adjusted operating margin is 26% for the quarter and 27% year to date. As we said, we also had an extraordinary general meeting to elect Mauricio as our new chairman. So we will now turn it over for any questions that you may have.

Operator
16:11 - 16:29

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the Pound Key on your telephone keypad. The next question comes from Christopher Lilienberg from DNB and Carnegie. Please go ahead.

Christopher Lilienberg
16:31 - 17:13

Yes. And that leads to a cash flow for the period of 107 million versus 111 million last year. It's good to hear that direct sales seem to be doing well. Is it possible to provide a figure for how large a share of the total sales that now represents? That's my first question. The second question is on the extra marketing investment, is it possible to quantify how that has impacted sales? You're talking about good momentum in the US. But maybe you could quantify that. And then, when it comes to the reason for weakness in Eastern Europe, is there anything particular there? If I remember correctly, you have one large distributor. I don't know if it's some destocking effects impacting there as well. Thank you.

Theresa Agnew
17:13 - 18:10

Yes. So the first question around what percentage of our sales the direct markets now represent, that's approximately 36% of our overall sales. And frankly, we anticipate that to continue to grow because as we expand the business in France, Germany, and Austria next year, it will become a larger percentage of our sales in terms of our marketing investment. The majority of our investment, by far, is in the US. We have also made some smaller investments in the UK, Canada, and Australia. But the US business is doing extremely well. So, you know, there's over 20% growth in the US. So very strong results from our investments around marketing and media. In terms of Eastern Europe. You are right. We have one large distributor.

Christopher Lilienberg
18:10 - 18:23

Before. Sorry, before Eastern. Could I ask a follow-up on these two? So the 20% growth in the US, I guess that's currency-adjusted. Is that in the quarter or year to date?

Theresa Agnew
18:24 - 18:34

Uh, so that's overall year to date. We look at year-to-date figures, which are similar to those in the quarter itself.

Christopher Lilienberg
18:35 - 18:49

You're talking about good momentum in the US. That's very helpful. Thank you. And just on the first one, the 46% overall, or 46% share of direct sales, is that in the quarter or the last month?

Theresa Agnew
18:49 - 18:50

That's in the quarter.

Christopher Lilienberg
18:52 - 18:55

Perfect. Thank you. Yes. And then my final question. Sorry.

Theresa Agnew
18:55 - 19:21

Yes. And then in Eastern Europe, you are right. We have one partner, Ewopharma, that covers about 16 markets across Eastern Europe. And there is some order variability happening there. So we anticipate that there will be increased orders and transferability from one quarter to another. In terms of those markets.

Christopher Lilienberg
19:24 - 19:25

Thank you very much.

Operator
19:31 - 19:35

The next question comes from Matthias Radstone from SEB. Please proceed.

Unknown 1
19:38 - 20:17

Good morning. Thanks for taking my questions. First, I was curious to hear a bit more about EMEA. So maybe if you could quantify what impact the transition to own sales had in Q3 year over year on growth? And yeah, if that's a reason at all for EMEA declining here. And also, if you can talk about the impact this could have on organic growth for the coming quarters. And if you foresee EMEA returning to growth in the near term based on variability in Eastern Europe, that's the first one. Thanks.

Theresa Agnew
20:17 - 21:40

Yes. In terms of own sales in EMEA, because we have taken France direct, we have seen a year-to-date decline in sales as our partner has been selling through their inventory and not ordering from us. So we started selling in Q2, but in very small amounts. So now we're starting to see that pick up as expected. So whenever we take a market direct, we anticipate that there will be lower sales for a period of time, and then it will start to grow as inventory is sold through in the markets. Thank you. So that is the own markets. The shift to own sales is a reason for the decline in EMEA around France. And France is a very big market for us in EMEA. So you know, that, of course, can be offset by some of the other markets, but they're much smaller. So, Finland as an owned market, is growing really well. The UK as an owned market is growing at double digits. But because France is such a large market for us in Europe, it offsets those.

Unknown 1
21:42 - 21:57

Thanks. That was what I thought as well. And in terms of Germany and Austria, could you elaborate on how we should view that transition, specifically how it looked in Q3 and how we can expect these markets to develop?

Theresa Agnew
21:57 - 22:30

So you know, that of course can be offset by some of the other markets, but they're much smaller. So, good question. So we will see a similar effect with Germany and Austria, where we will see some declining orders. In terms of the partner ordering from us. And they will be selling through their inventory into next year. So we will be able to start selling. And so, just like France, we will see a period of time where we will start to increase sales early next year and then see more benefits in the second half.

Unknown 1
22:32 - 22:35

So you know, that of course can be offset by some of the other markets, but they're much smaller. Would you say this effect was already present in Q3?

Theresa Agnew
22:35 - 22:38

I'm sorry. So you know, that of course can be offset by some of the other markets, but they're much smaller.

Unknown 1
22:38 - 23:17

Did you say the impact? Yeah. So you know, that of course can be offset by some of the other markets, but they're much smaller. That was present in Q3. Yes. So you know, that of course can be offset by some of the other markets, but they're much smaller. That all makes sense. So you know, that of course can be offset by some of the other markets, but they're much smaller. And then. Yes. Regarding operating expenses. It has been up with some variability, but around 20% for the past quarters now. So I'm just looking ahead. In Q4 last year, you experienced a significant increase in operating expenses. Yes. Do you foresee operating expenses growth slowing down a bit in the upcoming quarters, or how should we interpret that? Thank you.

Alexander Kotsinas
23:19 - 23:41

Yes. So the opex, I think in the fourth quarter, normally we experience seasonal effects where we have increased opex in the fourth quarter, for example, in the US market. Without providing any guidance, our costs normally increase somewhat in the fourth quarter.

Unknown 1
23:43 - 24:16

Perfect. Then I have one final question, if that's okay. The new patented strain that you bring up in the presentation. BGR 46. If you could just talk a bit in general about this and maybe how it will be included in your broad product offering that you have today, and then the potential combination with DSM 1793 in colic drops, for instance. Yes. Could you provide a general overview of how you envision that? So I'm just looking ahead. Being included in the offering?

Theresa Agnew
24:16 - 25:20

So I'm just looking ahead. So, yes. BGR 46 is an important strain for us. Uh, for the future. So it is a patented strain that we will include in new products. So we have talked before about how we aim to launch a new product that will be a combination of our DSM 17 strain and our new patented strain. So this is the new patented strain that will then be in combination with the DSM 1793 strain in new products. And so we will have more information out on that in the near future. You know, we are conducting a clinical study on a new drug product. More to come on that when we get our results in, but we will be including this strain in multiple new products across what we call our 'grow the core.' So it will be in colic-oriented products. It will be in other categories as well. Immune health, gut health, and so forth.

Unknown 1
25:23 - 25:24

Very clear answer. Thank you very much.

Operator
25:30 - 25:34

The next question comes from Matthias Häggblom from Handelsbanken. Please go ahead.

Unknown 2
25:37 - 26:17

Good morning. Thanks so much. I have two questions, please. So firstly, with a new chairman as well as a new principal shareholder, I'm curious to hear how the board's work has changed, if at all. And then, secondly, somewhat related to this, I guess we're in the midst of budget planning heading into '26. So with OpEx up 29% year to date, investor feedback suggests this remains a focus area, so at least help me think about the pace of OpEx going into 2026. At least directionally.

Theresa Agnew
26:18 - 27:07

Very clear answer. So in terms of the board, with Morita as our new chairman, we have had two board meetings where we have talked about numerous things. We have also updated our strategic plan. So that has been included in all of our discussions with our new chairman. We will be conducting, as a typical part of our process, a strategic review regarding our strategic plan with the board in the upcoming meetings. So that's a normal part of how we operate. However, Maurizio has now been involved in two board meetings thus far since August. And then if Alex wants to talk a little bit about OpEx, I think you had a question on the OpEx.

Alexander Kotsinas
27:09 - 27:43

So basically, we do have this ambition. Of course, our financial target is to achieve a 34% margin, and we're not there at the moment. And our ambition is to improve this going forward. We will improve our EBIT margin going forward without specifying exactly when, but that is our ambition for next year. So basically, our OpEx will not grow to the same extent as our gross profit will grow. It will grow to a lesser extent.

Theresa Agnew
27:43 - 28:06

And also just to add to that, as you know, with our direct markets, we have a level of investment that we do with the direct markets. We run a very lean organization. So we don't have a lot of fixed costs. But we are making investments in those direct markets of France as well as Germany.

Unknown 2
28:10 - 28:28

Thank you. I have one follow-up. So if OpEx is up 29% year to date and sales in the US are up over 20%, where a majority of the investments have been targeted, how do investors build confidence that these investments actually generate and translate into a good return?

Theresa Agnew
28:30 - 29:23

Yes. Regarding future growth, we can observe some of the aspects we've discussed concerning direct markets. So France and Germany, for instance, we have a lot of confidence in terms of how we will grow in those markets for the future. So France is an extremely important European market for us. And frankly, in Germany, we anticipate growing our business substantially because, in the past, it has been one of the smaller European businesses for us, so we want to really focus on that market as well. So if you look at where we're investing, we anticipate seeing growth in those markets where we are investing: France, Germany, US, and Canada.

Unknown 3
29:27 - 29:28

I think everyone is aligned that the direct, go-direct-to-market initiatives have worked favorably.

Unknown 2
29:28 - 30:01

It is aligned that these direct, go-to-market initiatives have worked favorably. I think, if there is a debate, it revolves more around these shorter-term campaign investments, so to say. So, I heard you say the majority of the investment this year has been for the US, and the US is up less than the OpEx for the group year to date. So. Is there any way you can share your confidence in that these more campaign-related investments also translate into permanent good returns?

Theresa Agnew
30:02 - 30:23

Yes. Yes. I mean, they are translating into good returns for us in the US. So if you look at our spending in the US, we are driving considerable growth, as I said, over 20%. So, but there's also currency impacts in terms of the US dollar.

Unknown 3
30:27 - 30:28

Okay.

Unknown 2
30:28 - 30:38

So the 20% includes the headwind from FX. So in local currency, the growth year to date in the US may be even higher than 20%.

Alexander Kotsinas
30:38 - 30:39

That's correct.

Unknown 4
30:39 - 30:40

That's correct. Okay.

Unknown 2
30:41 - 30:43

That's very helpful. Thank you so much.

Operator
30:47 - 31:15

As a reminder, if you wish to ask a question, please press the pound key on your telephone keypad. The next question comes from Christopher Lilienberg from NB Carnegie. Please go ahead. Christopher Lilienberg, your line is now unmuted. Please go ahead.

Christopher Lilienberg
31:17 - 31:30

Thank you. Two follow-up questions from me. I think you said that France had a record month in September. Is that also compared with the previous distributor sales in a given month?

Theresa Agnew
31:32 - 31:49

We don't track it by the previous distributor's sales in a given month. We don't have all of that information from our distributors. But just in terms of our sales in the French market.

Christopher Lilienberg
31:52 - 32:01

Okay. But I mean, is this growth since you started to sell directly, or is it related to shipments or sales you booked to a distributor? Previously in a given month as well.

Theresa Agnew
32:01 - 32:17

Yes, yes. So it's compared to our sales. Regarding the distributor in a particular month. So we don't always get all of the sellout information and what the sales are in the market from our partners.

Christopher Lilienberg
32:18 - 32:30

Yeah, but that sounds very positive, given that there must have been some months where the previous distributors built up inventory, etc. .

Theresa Agnew
32:30 - 32:57

Please go ahead. Yeah, it is very positive for us. And also with us taking this market direct, we now have a broader opportunity for distribution. We're still working on this. But the sales force that we have hired actually has access to even more distribution points than our previous partner. So one of our goals is to drive our distribution further.

Unknown 3
32:59 - 32:59

Please go ahead.

Christopher Lilienberg
32:59 - 33:17

Thank you. And then, it's nice to see the Pediatric segment improving here in the quarter. And I think, Alex, you mentioned some price adjustments, etc. It sounds like this should be a sustainable level, or were there some very positive mix effects in the quarter that explain this?

Alexander Kotsinas
33:19 - 33:28

It's always difficult to know exactly. However, we hope it is fairly sustainable. Yes, unless there are some negative surprises, it should be sustainable.

Unknown 3
33:30 - 33:31

Great.

Christopher Lilienberg
33:31 - 33:31

Thank you so much.

Operator
33:35 - 33:41

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Theresa Agnew
33:41 - 33:53

Thank you for your questions. We appreciate the time to review our Q3 results, and we will speak with you again for next quarter. It's always difficult to know exactly.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…